Wilbert van Duijnhoven

623 total citations
13 papers, 214 citations indexed

About

Wilbert van Duijnhoven is a scholar working on Epidemiology, Infectious Diseases and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Wilbert van Duijnhoven has authored 13 papers receiving a total of 214 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Epidemiology, 5 papers in Infectious Diseases and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Wilbert van Duijnhoven's work include Influenza Virus Research Studies (6 papers), Respiratory viral infections research (6 papers) and Viral Infections and Immunology Research (3 papers). Wilbert van Duijnhoven is often cited by papers focused on Influenza Virus Research Studies (6 papers), Respiratory viral infections research (6 papers) and Viral Infections and Immunology Research (3 papers). Wilbert van Duijnhoven collaborates with scholars based in United States, Belgium and Netherlands. Wilbert van Duijnhoven's co-authors include Lorant Leopold, David Anderson, Teddy Kosoglou, Robert S. Kauffman, Johan Vingerhoets, Robert W. Finberg, Roman Fleischhackl, Jónas Ingimarsson, Mae O. Gordon and H. J. Sparr and has published in prestigious journals such as The Journal of Infectious Diseases, Vaccine and British Journal of Anaesthesia.

In The Last Decade

Wilbert van Duijnhoven

12 papers receiving 208 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wilbert van Duijnhoven United States	6	116	51	42	39	33	13	214
Guangzhi Shi China	9	62 0.5×	26 0.5×	15 0.4×	28 0.7×	31 0.9×	31	227
Wen Ouyang United States	6	141 1.2×	26 0.5×	64 1.5×	9 0.2×	9 0.3×	11	220
Maria Carolina Paulino Portugal	7	43 0.4×	78 1.5×	19 0.5×	10 0.3×	7 0.2×	15	177
Antonella Potalivo Italy	6	14 0.1×	30 0.6×	24 0.6×	19 0.5×	25 0.8×	7	111
Dominique Falcon France	5	82 0.7×	14 0.3×	43 1.0×	4 0.1×	21 0.6×	6	241
Laura Marchesini Italy	4	17 0.1×	47 0.9×	15 0.4×	10 0.3×	23 0.7×	4	95
Haitao Yang China	9	14 0.1×	6 0.1×	7 0.2×	17 0.4×	44 1.3×	17	136
R Oggioni Italy	6	100 0.9×	6 0.1×	15 0.4×	9 0.2×	46 1.4×	12	196
Mireille Adda France	5	27 0.2×	8 0.2×	33 0.8×	4 0.1×	6 0.2×	15	108

Countries citing papers authored by Wilbert van Duijnhoven

Since Specialization

Citations

This map shows the geographic impact of Wilbert van Duijnhoven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilbert van Duijnhoven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilbert van Duijnhoven more than expected).

Fields of papers citing papers by Wilbert van Duijnhoven

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilbert van Duijnhoven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilbert van Duijnhoven. The network helps show where Wilbert van Duijnhoven may publish in the future.

Co-authorship network of co-authors of Wilbert van Duijnhoven

This figure shows the co-authorship network connecting the top 25 collaborators of Wilbert van Duijnhoven. A scholar is included among the top collaborators of Wilbert van Duijnhoven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilbert van Duijnhoven. Wilbert van Duijnhoven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Equils, Ozlem, Shawn Flanagan, Johan Vingerhoets, et al.. (2025). 573. CD388, a Novel Drug-Fc Conjugate (DFC), Demonstrates Prophylactic Activity in an Influenza Human Challenge Model. Open Forum Infectious Diseases. 12(Supplement_1).

Leopold, Lorant, Johan Vingerhoets, Karin Weber, et al.. (2024). Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection. The Journal of Infectious Diseases. 231(1). e132–e143. 3 indexed citations

Langley, Joanne M., Terry Nolan, Mika Rämet, et al.. (2024). A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12–24 Months. Open Forum Infectious Diseases. 11(9). ofae453–ofae453. 2 indexed citations

Vingerhoets, Johan, Ilse Van Dromme, Wilbert van Duijnhoven, et al.. (2023). Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study. Antiviral Therapy. 28(3). 211900033–211900033. 3 indexed citations

Duijnhoven, Wilbert van, et al.. (2022). The Hospital Recovery Scale: A clinically useful endpoint in patients hospitalized with influenza. Contemporary Clinical Trials. 123. 106952–106952. 5 indexed citations

O’Neil, Brian J., Michael G. Ison, Anna Nilsson, et al.. (2020). A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study. The Journal of Infectious Diseases. 226(1). 109–118. 22 indexed citations

Finberg, Robert W., David Anderson, Roman Fleischhackl, et al.. (2018). Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial. The Journal of Infectious Diseases. 219(7). 1026–1034. 87 indexed citations

Douoguih, Macaya, Neil Goldstein, Stephan Bart, et al.. (2016). Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults. Journal of Virus Eradication. 2. 10–11. 1 indexed citations

Milligan, Iain, Malick M. Gibani, Danielle Campbell, et al.. (2015). Heterologous Prime-Boost Schedules of Replication-Defective Adenovirus Serotype 26 and Modified Vaccinia Virus Ankara Vector Vaccines Expressing Ebola Virus Glycoprotein Are Immunogenic and Well Tolerated in Healthy Adults. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations

10.

Heldens, Jacco, Ellen G. J. Hulskotte, Paul E. Verweij, et al.. (2014). Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: A Phase I dose escalating study in healthy volunteers. Vaccine. 32(39). 5118–5124. 7 indexed citations

11.

Szegedi, Armin, Paul E. Verweij, Wilbert van Duijnhoven, et al.. (2012). Meta-Analyses of the Efficacy of Asenapine for Acute Schizophrenia. The Journal of Clinical Psychiatry. 73(12). 1533–1540. 26 indexed citations

12.

Szegedi, Armin, Paul E. Verweij, Wilbert van Duijnhoven, et al.. (2011). Meta-analysis of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other atypical antipsychotics. European Psychiatry. 26(S2). 1511–1511. 1 indexed citations

13.

Pühringer, F., Mae O. Gordon, Ignace Demeyer, et al.. (2010). Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose–response relationship. British Journal of Anaesthesia. 105(5). 610–619. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact